These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31424656)

  • 1. Low expression of TUG1 promotes cisplatin sensitivity in cervical cancer by activating the MAPK pathway.
    Wei X; Zhou Y; Qiu J; Wang X; Xia Y; Sui L
    J BUON; 2019; 24(3):1020-1026. PubMed ID: 31424656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TUG1 promotes the development of prostate cancer by regulating RLIM.
    Guo BH; Zhao Q; Li HY
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):1926-1933. PubMed ID: 30915735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA TUG1 aggravates the progression of cervical cancer by binding PUM2.
    Duan W; Nian L; Qiao J; Liu NN
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8211-8218. PubMed ID: 31646551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA TUG1 promotes cisplatin resistance in esophageal squamous cell carcinoma cells by regulating Nrf2.
    Zhang Z; Xiong R; Li C; Xu M; Guo M
    Acta Biochim Biophys Sin (Shanghai); 2019 Aug; 51(8):826-833. PubMed ID: 31287493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taurine up-regulated 1 accelerates tumorigenesis of colon cancer by regulating miR-26a-5p/MMP14/p38 MAPK/Hsp27 axis in vitro and in vivo.
    Tian L; Zhao ZF; Xie L; Zhu JP
    Life Sci; 2019 Dec; 239():117035. PubMed ID: 31697952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer potential of TUG1 knockdown in cisplatin-resistant osteosarcoma through inhibition of MET/Akt signalling.
    Zhou Q; Hu T; Xu Y
    J Drug Target; 2020 Feb; 28(2):204-211. PubMed ID: 31305159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
    Cai Y; Dong ZY; Wang JY
    Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LINC00460 knockdown sensitizes cervical cancer to cisplatin by downregulating TGFBI.
    Tian P; Feng Y; Tao L
    Chem Biol Drug Des; 2024 Jan; 103(1):e14424. PubMed ID: 38230774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TMEM45A Affects Proliferation, Apoptosis, Epithelial-Mesenchymal Transition, Migration, Invasion and Cisplatin Resistance of HPV-Positive Cervical Cancer Cell Lines.
    Liu Y; Liu L; Mou ZX
    Biochem Genet; 2022 Feb; 60(1):173-190. PubMed ID: 34143331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of microRNA-4739 in enhancing cisplatin chemosensitivity by negative regulation of RHBDD2 in human cervical cancer cells.
    Li Y; Zhou Z; Qu J; Gong P; Wei Y; Sun Y
    Cell Mol Biol Lett; 2024 Jan; 29(1):20. PubMed ID: 38267862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of long noncoding RNA TUG1 promotes cervical cancer cell proliferation and migration.
    Hu Y; Sun X; Mao C; Guo G; Ye S; Xu J; Zou R; Chen J; Wang L; Duan P; Xue X
    Cancer Med; 2017 Feb; 6(2):471-482. PubMed ID: 28088836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long Non-Coding RNA TUG1 Promotes Proliferation and Inhibits Apoptosis of Osteosarcoma Cells by Sponging miR-132-3p and Upregulating SOX4 Expression.
    Li G; Liu K; Du X
    Yonsei Med J; 2018 Mar; 59(2):226-235. PubMed ID: 29436190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPP1 inhibition improves the cisplatin chemo-sensitivity of cervical cancer cell lines.
    Chen X; Xiong D; Ye L; Yang H; Mei S; Wu J; Chen S; Mi R
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):603-613. PubMed ID: 30627777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probing the Effects of Retinoblastoma Binding Protein 6 (RBBP6) Knockdown on the Sensitivity of Cisplatin in Cervical Cancer Cells.
    Mehta H; Ambele MA; Mokgautsi N; Moela P
    Cells; 2024 Apr; 13(8):. PubMed ID: 38667315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long non-coding RNA TUG1 sponges miR-197 to enhance cisplatin sensitivity in triple negative breast cancer.
    Tang T; Cheng Y; She Q; Jiang Y; Chen Y; Yang W; Li Y
    Biomed Pharmacother; 2018 Nov; 107():338-346. PubMed ID: 30098551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TUG1 knockdown ameliorates atherosclerosis via up-regulating the expression of miR-133a target gene FGF1.
    Zhang L; Cheng H; Yue Y; Li S; Zhang D; He R
    Cardiovasc Pathol; 2018; 33():6-15. PubMed ID: 29268138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [EBF1 Promotes the Sensitivity of Cervical Cancer Cells to Cisplatin via Activating FBN1 Transcription].
    Shen NN; Lin JH; Liu PP
    Mol Biol (Mosk); 2023; 57(3):503-504. PubMed ID: 37326054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of LncRNA TUG1 enhances radiosensitivity in bladder cancer via suppressing HMGB1 expression.
    Jiang H; Hu X; Zhang H; Li W
    Radiat Oncol; 2017 Apr; 12(1):65. PubMed ID: 28376901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MALAT1 promotes cisplatin resistance in cervical cancer by activating the PI3K/AKT pathway.
    Wang N; Hou MS; Zhan Y; Shen XB; Xue HY
    Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):7653-7659. PubMed ID: 30536307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PCAT1 promotes the proliferative and migratory potentials of ovarian cancer via targeting NEK2.
    Liu XL; Liu HM; Han N; Li FH; Sun F; Fan DM; Xu Q
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8239-8248. PubMed ID: 31646554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.